Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Crimson Cinnamon Bark (Cinnamomum osmophloeum) is a Taiwanese endemic tree whose bark essential oil contains 62–77% trans-cinnamaldehyde, a bioactive aldehyde demonstrated in preclinical models to activate AMP-activated protein kinase (AMPK) signaling, enhance GLUT4-mediated glucose uptake, and exert potent anti-inflammatory and antimicrobial effects. Although no human clinical trials specific to C. osmophloeum bark have been indexed in PubMed to date, phytochemical analyses published in the Journal of Agricultural and Food Chemistry and reviews in Evidence-Based Complementary and Alternative Medicine confirm its rich cinnamaldehyde profile and broad-spectrum bioactivity comparable to Cinnamomum verum and C. cassia.
Reported Benefits (Provisional)
Origin & History
Crimson Cinnamon Bark (Cinnamomum spp.) is derived from trees native to tropical rainforests and highland regions of Southeast Asia, the Indian subcontinent, and Central America. It is prized for its aromatic bark and its historical use in metabolic regulation and cardiovascular support.
Research Narrative (Provisional)
Phytochemical characterization studies published in the Journal of Agricultural and Food Chemistry have confirmed that Cinnamomum osmophloeum bark essential oil is dominated by trans-cinnamaldehyde at 62–77% of total volatiles, positioning it among the most cinnamaldehyde-rich Cinnamomum species. A comprehensive review in Evidence-Based Complementary and Alternative Medicine (2014) evaluated antioxidant, anti-inflammatory, antidiabetic, and antimicrobial activities of multiple Cinnamomum species including C. osmophloeum, noting significant free-radical scavenging and NF-κB pathway inhibition in vitro. A widely cited multifaceted review by Rao and Gan (2014) in BMC Complementary and Alternative Medicine (PMC4003790) catalogued the pharmacological activities of cinnamon-derived cinnamaldehyde, including insulin-mimetic effects and lipid-lowering properties across rodent models. No human randomized controlled trials specific to C. osmophloeum bark have yet been indexed in PubMed, underscoring the need for translational clinical research.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Phytochemicals: Polyphenols (cinnamaldehyde, eugenol, catechins), Flavonoids (quercetin, kaempferol, myricetin), Volatile oils (cinnamate, benzyl benzoate, safrole), Coumarins. - Fiber: Soluble and insoluble fiber. - Vitamins: Vitamin K. - Minerals: Manganese, iron.
Reported Mechanism (Provisional)
Trans-cinnamaldehyde (62–77% of bark oil) activates AMP-activated protein kinase (AMPK), a master cellular energy sensor, which in turn phosphorylates acetyl-CoA carboxylase (ACC), suppressing de novo lipogenesis and promoting fatty acid oxidation in hepatocytes. AMPK activation simultaneously stimulates translocation of glucose transporter type 4 (GLUT4) to the plasma membrane of skeletal muscle and adipose cells, enhancing insulin-independent glucose uptake and improving glycemic control. The compound also inhibits nuclear factor kappa-B (NF-κB) signaling by blocking IκB kinase (IKK) phosphorylation, thereby reducing expression of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. Additionally, cinnamaldehyde modulates Nrf2/ARE antioxidant response pathways, upregulating endogenous antioxidant enzymes such as superoxide dismutase (SOD), catalase, and heme oxygenase-1 (HO-1), which collectively attenuate oxidative stress.
Clinical Narrative (Provisional)
Current evidence for Crimson Cinnamon Bark relies primarily on preclinical in vitro and animal studies rather than human clinical trials. Research demonstrates that trans-cinnamaldehyde and CB403 (synthesized from bark compounds) inhibit tumor cell growth in laboratory cultures and animal models. While general cinnamon bark studies show metabolic and cardiovascular benefits in humans, specific quantified clinical outcomes for C. osmophloeum bark are lacking. Further randomized controlled trials with defined dosages and measured endpoints are needed to establish clinical efficacy.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.